Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation

Autor: Fujun Miao, Xuan-jun Wang, Jun Sheng, Jindong Kong, Chuanqi Xie
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Pulmonary and Respiratory Medicine
erlotinib
EGFR H773_V774 insH mutation
Lung Neoplasms
Mice
Nude
combination effects
lcsh:RC254-282
Flow cytometry
EGFR Exon 20 Insertion Mutation
Erlotinib Hydrochloride
Mice
03 medical and health sciences
0302 clinical medicine
Ellagic Acid
Carcinoma
Non-Small-Cell Lung
Cell Line
Tumor
Antineoplastic Combined Chemotherapy Protocols
medicine
Animals
Humans
Epidermal growth factor receptor
Clonogenic assay
Protein Kinase Inhibitors
Ba/F3 cell line
biology
medicine.diagnostic_test
Cell growth
business.industry
Original Articles
General Medicine
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
respiratory tract diseases
030104 developmental biology
Oncology
Apoptosis
Cell culture
030220 oncology & carcinogenesis
Mutation
Cancer research
biology.protein
Original Article
Erlotinib
business
medicine.drug
Zdroj: Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 8, Pp 2101-2111 (2020)
ISSN: 1759-7714
1759-7706
DOI: 10.1111/1759-7714.13487
Popis: Background Epidermal growth factor receptor H773_V774 insH (EGFR‐insH) is an EGFR exon 20 insertion mutation in non‐small cell lung cancer (NSCLC), which is naturally resistant to available EGFR tyrosine kinase inhibitors (TKIs) and lacks a patient‐derived cell line. Methods A Ba/F3 cell line expressing EGFR‐insH mutation (Ba/F3‐insH cell line) was generated using an IL3‐deprivation method. A cell proliferation assay was performed to screen natural compounds that exhibit a synergistic effect with erlotinib. Trypan blue staining was used to assess cell growth and crystal violate staining was recruited to evaluate clonogenic potential. Flow cytometry was used to detect EGFR expression and cell apoptosis. A xenograft model was created to evaluate the effect of ellagic acid (EA) with erlotinib on tumor growth. Results EA was identified to synergistically inhibit the proliferation of Ba/F3‐insH cells with erlotinib. The growth and clonogenic potential of Ba/F3‐insH cells were definitely constrained by EA with erlotinib, whereas, the apoptosis of Ba/F3‐insH cells was dramatically promoted by the combination. In a xenograft model of the Ba/F3‐insH cell line, the combination treatment also exhibited a synergistic reduction in tumor growth. Conclusions In this study, we generated a Ba/F3 cell line expressing EGFR H773_V774 insH mutation and identified a synergistic treatment (EA with erlotinib) that markedly inhibited the viability of Ba/F3‐insH cells in vitro and in vivo. Key points Our results indicated that the combination of ellagic acid with erlotinib has synergistic effects against EGFR H773_V774 insH mutation.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje